Abstract Dilated cardiomyopathy (DCM) is characterized by deteriorating cardiac performance, impaired contraction and dilation of the left ventricle (or both ventricles). Blood markers-known as "biomarkers"-allow insight into underlying pathophysiologic mechanisms and biologic pathways while predicting outcomes and guiding heart failure management and/or therapies. In this review, we provide an alternative approach to conceptualize heart failure biomarkers: the cardiomyocyte, its surrounding microenvironment, and the macroenvironment, integrating these entities which may impact cellular processes involved in the pathogenesis and/or propagation of DCM. Newer biomarkers of left ventricular systolic dysfunction can be categorized under: (a) myocyte stress and stretch, (b) myocyte apoptosis, (c) cardiac interstitium, (d) inflammation, (e) oxidative stress, (f) cardiac energetics, (g) neurohormones, and (h) renal biomarkers. Biomarkers provide insight into the pathogenesis of DCM while predicting and potentially providing prognostic information in these patients with heart failure.
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Keywords Biomarkers . Dilated cardiomyopathy . Heart failure Cardiomyopathy is defined as an alteration in the structure and function of the myocardium, leading to deterioration of myocardial performance often resulting in the development of clinical heart failure. Dilated cardiomyopathy (DCM), a common cardiomyopathy leading to heart failure, has a prevalence of 1:2,500 [1] and is characterized by enlargement of one or both of the ventricles with associated systolic dysfunction. Many diverse etiologies, either primary (solely or predominantly confined to the heart muscle) or secondary (myocardial involvement from a systemic disease process), may lead to the DCM phenotype. A diagnosis of DCM requires evidence of dilation and impaired contraction of the left ventricle or both ventricles (e.g., left ventricular ejection fraction (LVEF) <40 %) [2] . The disease is considered idiopathic if primary and secondary causes of heart disease are excluded. Of note, in the literature, the term DCM is usually an all-encompassing term for a nonischemic cardiomyopathy with depressed left ventricular (LV) function.
Macroscopically, DCM consists of hearts that are heavy (increased LV mass) with geometric changes indicating eccentricity (defined as low relative wall thickness-normal or reduced wall thickness in relation to a dilated LV chamber size) [3] . Microscopically, cardiomyocytes in DCM often consist of a classic histological triad-myocyte hypertrophy, myocyte loss, and interstitial fibrosis [4] . However, these findings are imprecise in identifying underlying etiologies for cardiomyopathies. In addition, the natural course of DCM can be variable, contingent on multiple factors, including etiology and initial cardiac phenotype of the cardiomyopathy, ongoing cardiac insults and genetic underpinnings of an individual's resistance to adverse cardiac remodeling.
Heart failure is a clinical syndrome that manifests as a consequence of the progression of the underlying cardiomyopathy. It is a complex process featuring pressure and/or volume overload leading to ventricular remodeling. Diverse etiologies, presentations, and outcomes are seen, thus making the classification of cardiomyopathies challenging. Equally challenging is categorizing biomarkers of heart failure as they are often described according to their mechanism (e.g., neurohormonal, oxidative stress, etc.). However, an alternative method to conceptualize biomarkers in heart failure is to approach the classification from three vantage points: the cardiomyocyte, its surrounding microenvironment, and the macroenvironment (Fig. 1) . In heart failure, the cardiac myocyte is subjected to many stressors-such as mechanical, oxidative, and pro-inflammatory, resulting in structural and functional changes (i.e., hypertrophy, necrosis/apoptosis, altered myocyte energetics, impaired contraction and relaxation). The myocyte "microenvironment," the environment immediately surrounding a myocyte, includes the cardiac interstitium, cardiac fibroblasts, and other factors that interact or cross-talk with cardiomyocytes. Lastly, the "macroenvironment" in heart failure refers to the interaction of the heart and other organ systems and the impact of those systems on the heart (e.g., insulin resistance, cardiac cachexia, obesity, cardiorenal syndrome, and ventricular-vascular coupling). The intimate relationship between the microenvironment and macroenvironment with the cardiomyocyte may result in downstream cellular or signaling changes which may be important in the initiation and propagation of DCM or reflect changes that have already taken place in DCM.
For the purpose of this review, emerging biomarkers in DCM will be the primary focus. Although 20-35 % of DCM has been genetically correlated with >20 loci and associated genes [1], genetic biomarkers are out of the scope of this review and will not be discussed. The biomarkers reviewed here are not unique to DCM, and we do not provide an exhaustive list (Table 1) but provide insight into underlying pathophysiologic mechanisms and biologic pathways important in, but not specific to, DCM. Some of these biomarkers may prognosticate outcomes, enable guidance in heart failure therapeutics, and be used for monitoring treatments in DCM.
The Cardiomyocyte
Myocyte Stress/Stretch One of the most well-described and studied biomarkers in heart failure and ventricular stress is B-type natriuretic peptide (BNP) and its amino-terminal fragment (NT-proBNP). Activation of the BNP gene (natriuretic peptide B), in response to myocardial stress (predominantly via stretch), results in the production of both peptides. Both biomarkers Fig. 1 Interaction of heart failure biomarkers between the cardiomyocyte, the microenvironment, and the macroenvironment. Stressors on the cardiac myocyte lead to structural and functional changes (hypertrophy, apoptosis, altered myocyte energetics, and contraction apparatus modifications). Microenvironment refers to the immediate environment of the myocyte-the interstitium, cardiac fibroblasts, and inflammatory mediators. Lastly, the macroenvironment includes other organ systems and their impact on the heart in heart failure (e.g., adipose tissue, cardiac cachexia, cardiorenal syndrome, neurohormones, and ventricular-vascular coupling). Clear overlap exists between these domains, contributing to the development and propagation of heart failure diagnose acute heart failure syndromes [5, 6] but without specifically predicting DCM or left ventricular systolic dysfunction (LVSD). Levels of NT-proBNP and BNP are both higher in patients with LVSD, but in substudies, modest correlations were seen predicting LVEF [7] [8] [9] . In a recent meta-analysis pooling biomarker-guided therapy trial data, a significant reduction in mortality was seen utilizing these natriuretic peptides in chronic heart failure management [10] but baseline LVEF was variable and with no specific analysis in DCM patients. Recently, however, the Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting study specifically looked at chronic LVSD (mean LVEF <30 %, of which a third were nonischemic in etiology) and found a statistically significant reduction in total cardiovascular event rates, improved quality of life, and reduction in LV chamber size as shown by LV end-systolic and end-diastolic volume indexes. Therefore NT-proBNP guided therapy may guide improvement in cardiac remodeling compared to standard of care [11] . Moreover, recent advances in BNP physiology have targeted the upstream 108-amino-acid prohormone of BNP and NT-proBNP, pro-BNP 1-108 , to identify asymptomatic LVSD in conjunction to known predictive abilities of BNP and NT-proBNP [12] [13] [14] .
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Atrial natriuretic peptide (ANP) is secreted predominantly from the atria during times of stretch, although it can be released from ventricular myocytes in times of ventricular stress [15] . ANP was recently evaluated in the context of the precursor pro-ANP peptide using a sandwich assay of the mid-regional sequence of ANP (MR-proANP), which is more stable and less susceptible to enzymatic degradation compared to ANP [16] . Two recent studies in patients with lower LVEF showed that elevated MR-proANP was able to identify LVSD and to predict mortality [17, 18] . Soluble ST2 (sST2) is a truncated soluble receptor of the interleukin (IL)-1 receptor family and is a biomarker of mechanical strain and fibrosis in conjunction with IL-33 (a ligand of ST2, synthesized by cardiac fibroblasts) [19, 20] . In a small cohort of DCM patients, sST2 (in addition to NTproBNP) predicted sudden cardiac death [21] . In acutely decompensated heart failure patients with depressed LVEF (median 34 %), sST2 levels predicted mortality risk [22] . In an echo substudy for the pro-BNP investigation of Dyspnea in the Emergency Room, sST2 levels correlated with cardiac structure (LV end-diastolic and end-systolic dimensions) in addition to predicting mortality [23] , indicating the potential utility of sST2 in predicting adverse cardiac remodeling.
Myocyte Injury
We will not discuss cardiac troponin I and T in this review, but refer the reader to Table 2 where other biomarkers not discussed in this review are listed. Cardiac troponins are the most common markers of myocyte necrosis. Release of troponin in heart failure is due to myocyte injury, regardless of the mechanism involved, and low circulating levels are present in chronic LVSD and DCM [24, 25] . [30, 126] Neurohormones Norepinephrine [127, 128] Renin [127] [128] [129] Aldosterone [130, 131] Angiotensin II [132] Arginine vasopressin [127, 133, 134] Myocyte Apoptosis
Heart-type fatty acid binding protein (H-FABP) is a cytosolic, nonenzymatic protein, which transports long-chain fatty acids into cardiomyocytes and is released into the circulation when the myocardium is injured [26] . In heart failure patients, H-FABP levels, together with cTnT, were more sensitive in detecting worse New York Heart Association (NYHA) functional class and identified a higher-risk group when cTnT levels were normal but H-FABP levels were elevated [27] . Several studies showed that H-FABP levels were strongly predictive of cardiac mortality and heart failure rehospitalizations in multivariate analyses [27] [28] [29] . Thus, its strength in prognosis is likely because this biomarker represents ongoing myocardial damage and identifies a higher-risk subset and likely provides insights into ongoing adverse cardiac remodeling. Similarly, soluble markers of apoptosis, specifically soluble apoptosis-stimulating fragment (sFAS), may eventually allow earlier prognostication in patients with heart failure. In low LVEF patients, sFAS independently predicted the composite outcome of all-cause mortality and rehospitalization for worsening heart failure [30] . Inflammatory mediators, such as IL-6 and tumor necrosis factor-alpha (TNF-α) (Table 2 ), appear to be important determinants of the FAS-FAS ligand pathway [31] -thus, the inflammatory milieu of heart failure contributes to the apoptotic process in patients with LVSD.
Myostatin (also known as growth differentiation factor [GDF]-8), a member of the transforming growth factor-beta (TGF-β) superfamily, is a secreted factor that inhibits muscle differentiation and growth. Myostatin is produced predominantly in skeletal muscle and is a negative regulator of skeletal muscle mass [32] . However, recent evidence now links myostatin to cardiomyocyte homeostasis, since myostatin is upregulated in patients with severe heart failure and DCM. Increased myostatin levels are seen as a possible protective counter-regulator of cardiomyocyte hypertrophy in advanced heart failure [33, 34] . A recent study in patients with depressed LVEF and heart failure (mean LVEF, 22.6 %) showed increased myostatin levels correlated with worsening NYHA classification [35] . Whether myostatin serum levels correlate with the skeletal muscle wasting phenomenon in heart failure and cardiac cachexia still remains to be studied.
The Microenvironment
Cardiac Interstitium
In DCM, the myocardial interstitium is in a constant state of flux with increased extracellular matrix turnover and decreased collagen linking, leading to a distorted and defective matrix architecture [36, 37] . A loss of alignment of the cardiomyocyte fascicles contributes to LV dilation and a loss of the matrixmyocyte interface likely weakening the myocyte-shortening force transduction, leading to impaired myocardial force and systolic performance [38] . Matrix metalloproteinases (MMPs), myocardial interstitium proteases that are pivotal in myocardial remodeling, are held in delicate balance by tissue inhibitors of matrix metalloproteinases (TIMPs) [39] . The overall change in matrix proteins in DCM favors increased MMP-mediated matrix proteolysis with upregulation noted in MMP-2, MMP-3, MMP-9, MMP-13, and MT1-MMP expression while decreases were seen in MMP-1 with varied responses of TIMP-1, TIMP-2, and TIMP-3. However, these findings were measured by tissue samples and not by blood protein characterization [36, 37, 40] . Plasma MMP-9 levels in the Randomized Evaluation of Strategies for LV Dysfunction (RESOLVED) study were inversely related to LV systolic function-suggesting a role for monitoring ongoing cardiac remodeling [41] . Plasma TIMP-1 levels correlated with cardiovascular risk factors, LV mass, and hypertrophy and were inversely associated with cardiac function (fractional shortening) in a community-based cohort [42] -suggesting that these proteins may provide early predictive information in patients at greatest risk for developing heart failure.
In addition to the regulators of collagen matrix formation, serum procollagen peptides have been evaluated to characterize and understand extracellular matrix turnover. Circulating amino-terminal propeptide of type III procollagen (PIIINP) portends a higher risk of death and hospitalization, particularly in lower LVEF patients [41] . Reverse remodeling after left ventricular assist device (LVAD) implantation supports an initial increase in serum N-terminal propeptide for type I collagen and PIIINP, thus providing insight into adverse cardiac remodeling [43] . Additional studies in a specific DCM cohort with serum markers are needed to further elucidate their role in risk prediction and prognosis.
Galectin-3, a β-galactoside-binding protein secreted by immune cells, has been associated with myocardial fibrosis, ventricular remodeling, and LV dysfunction [44, 45] . In two recent studies evaluating chronic heart failure patients, galectin-3 predicted mortality and heart failure hospitalization and correlated positively with LV end-systolic and enddiastolic volumes [46, 47] . Similarly, galectin-3 was associated with all-cause mortality and an increased risk of incident heart failure, thus implicating the predictive role of galectin-3 in detecting asymptomatic fibrosis and early adverse remodeling [48] .
Inflammation
Many markers of inflammation have been implicated in the pathogenesis of heart failure, with TNF-α being one of the most well studied [49, 50] . We will not be discussing TNF-α in this review (for references, see Table 2 ).
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK), a member of the TNF family, is a transmembrane protein that is released in a truncated, active form to bind to fibroblast growth factor-inducible 14 (Fn14). Fn14 is a highly inducible cell surface receptor that is involved in multiple signaling pathways, including the nuclear factor kappa B (NF-κB) pathway. TWEAK plays a role in cardiomyocyte proliferation, myocardial hypertrophy, and cardiac fibrosis during cardiac remodeling. However, there is conflicting data about the use of TWEAK levels as a biomarker. On one hand, increased levels of TWEAK after myocardial infarction with cardiac remodeling have been shown to portend adverse outcomes [51] . Conversely, lower levels of soluble TWEAK have been associated with increased mortality in heart failure patients [52, 53] . Thus, the role of TWEAK in heart failure and LVSD requires further clarification.
Osteoprotegerin (OPG), a member of the TNF receptor superfamily, binds to the receptor activator of NK-κB ligand (RANKL) and prevents the interaction between RANKL and its receptor. In a cohort of stable heart failure patients with LVSD (mean LVEF 32 %) with both ischemic and nonischemic etiologies, OPG levels were elevated in heart failure patients compared to controls and were positively correlated with worse NYHA functional class, degree of myocardial dysfunction (cardiac index), and neurohormonal activation (N-BNP) [54] . Additionally, in chronic heart failure patients, OPG levels are associated with mortality, independent of other risk factors of death. Thus, OPG levels may assist in risk stratification in these patients [55] .
Pentraxin-3 (PTX3), a member of the pentraxin superfamily (which includes C-reactive protein and serum amyloid P), is an inflammatory marker that is part of the innate immunity system which is produced by endothelial cells, smooth muscle cells, and macrophages [56] . PTX3, not C-reactive protein, proved to be an independent predictor of adverse eventsincluding all-cause mortality and hospitalization for worsening heart failure in several heart failure studies including GISSI-heart failure and CORONA cohorts [57, 58] .
Cardiotrophin-1 (CT-1) is a cytokine member of the IL-6 family. CT-1 mediates its effects by interacting with the glycoprotein 130/leukemia inhibitory factor receptor beta heterodimer. It has potent hypertrophic and survival effects on cardiac myocytes. CT-1 activates phosphatidylinositol 3-kinase in cardiac myocytes and enhances transcription factor NF-κB DNA-binding activities. CT-1 levels are increased in patients with DCM and are significantly correlated with the LV mass index, suggesting that CT-1 plays an important role in structural LV remodeling [59] .
Oxidative Stress
Increased oxidative stress is characterized by the excessive production of reactive oxygen species (ROS) which overwhelms the host's antioxidant defenses and is present in many cardiovascular disorders. Increased ROS in heart failure may mediate many pathways that play a role in adverse cardiac remodeling including the propagation of apoptosis, deleterious effects on endothelial function, activation of neurohormonal systems [60] , as well as direct effects on cardiomyocytes impairing cardiac performance (i.e., ROS-induced structural modifications of the sarcomere) [61] . Many methods exist to characterize the levels of ROS; however, only recently have there been human studies evaluating biomarkers that measure indirect markers of free radicals and assess their role in heart failure.
One biomarker of interest is myeloperoxidase (MPO), a leukocyte-derived heme peroxidase that is associated with neutrophil activation and inflammation with direct effects on ventricular remodeling in the post-infarct setting [62, 63] . In patients with LVEF <35 %, MPO was associated with right ventricular dysfunction and a more restrictive diastolic dysfunction pattern on echocardiography. MPO was also more predictive of increased future adverse clinical events even after multivariate adjustment [64] . In addition, combined with other markers of inflammation (like high-sensitivity Creactive protein), MPO levels provided incremental risk prediction in chronic systolic heart failure patients [64] . Thus, MPO levels may also provide a means for monitoring antiinflammatory effects with heart failure therapy [65] and help determine ongoing risk in heart failure patients.
Another marker of oxidative stress, plasma oxidized lowdensity lipoprotein (oxLDL) levels, was shown to be elevated in the coronary sinus of the heart compared to aortic root samples in DCM patients [66] . This transcardiac gradient of oxLDL correlates inversely with LV systolic function, as oxLDL levels are an independent predictor of mortality and adverse cardiac events in heart failure patients [66] [67] [68] .
The Macroenvironment
Myocyte Energetics
Alterations in cardiac metabolism and energy substrate utilization have been described as pathological consequences as well as therapeutic targets for heart failure [69, 70] . Adipokines are secreted by adipose tissue and are implicated as playing a role in the pathogenesis of heart failure [71, 72] . Adiponectin, an insulin-sensitizing hormone, is secreted not only by adipose tissue but also cardiomyocytes during cardiac stress. Adiponectin activates adenosine monophosphate-activated protein kinase, leading to downstream effects such as inhibiting cardiac hypertrophy as well optimizing energetics by preferentially supporting the major cardiomyocyte fuel, fatty acids, which are responsible for ∼70 % of the cardiac energy needs [73] . Changes in serum adipokine levels and adiponectin resistance between compensated and decompensated heart failure may be altered with LVAD therapy [74, 75] . Adiponectin modulates cardiac dysfunction by its interaction with several intracellular signaling pathways [76] . Depressed levels of adiponectin reflect greater cardiovascular risk and inflammation in conditions such as hypertension, coronary artery disease, obesity, and insulin resistance [77] [78] [79] . On the contrary, in humans with LVSD and heart failure [33, 80, 81] , adiponectin levels are elevated [71] and associated with the severity of heart failure symptoms, disease severity, and mortality [80, 82, 83] . It has been proposed that elevated adiponectin in LVSD is a state of "adiponectin resistance" and reflects an attempt to mitigate proinflammatory or impaired metabolic states and demonstrates a balance between protective and harmful pathways in the failing heart.
Neurohormones
Neurohormones such as norepinephrine, renin, angiotensin II, and aldosterone (for references, see Table 2 ) have been well described in prior reviews of biomarkers in heart failure [60] . Novel neurohormones include adrenomedullin (ADM), a peptide released by many tissue types, including the kidney and adrenal medulla, in the setting of pressure and volume overload. ADM belongs to the calcitonin generelated peptide family and is implicated in vasodilation via nitric oxide with resultant cardioprotective effects such as increasing cardiac output, decreasing afterload, and modulating cardiac fibroblast proliferation [84] . Mid-region pro-ADM, a stable prohormone fragment of ADM that is easier to measure, independently predicted 2-year mortality, particularly in LVSD with nonischemic etiology and NYHA class II or worse functional class [85] .
Copeptin, the C-terminal portion of the precursor peptide of the neurohormone arginine vasopressin (AVP or antidiuretic hormone), is a surrogate biomarker for AVP, which exerts its primary effects in the hypothalamus by stimulating the adrenocorticotropic hormone on vascular tissue (causing vasoconstriction), and in the kidneys (resulting in water retention). Increased copeptin levels in LVSD populations are linked to decreased survival rates, particularly in symptomatic NYHA class II-IV heart failure patients [86] . In the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan neurohormonal substudy which included a mixed population of acute heart failure syndrome plus LVSD patients, copeptin levels were a predictor of mortality post-myocardial infarction and performed better than BNP and NT-proBNP levels [87] .
Renal Markers
The relationship between renal dysfunction and heart failure is tightly intertwined with the activation of neurohormones and release of stress biomarkers that are associated with adverse cardiac outcomes [88] . Neutrophil gelatinaseassociated lipocalin (NGAL) is secreted by many cell types including renal tubule cells, hepatocytes, endothelial cells, and smooth muscle cells in response to cellular stress, inflammation, and ischemia [89] . NGAL, in patients with acutely decompensated heart failure at the time of discharge, was a strong predictor of 30-day heart failure readmissions and all-cause mortality [90] . In addition, NGAL predicted acute kidney injury in heart failure patient with LVSD [91] and correlated strongly with markers of anemia even after multivariate adjustment, such as renal function and markers of inflammation [92] , suggesting that NGAL which is initially produced as a compensatory response and may not simply be a risk marker but an active player in the heart failure syndrome.
Beta-trace protein (BTP), a glycoprotein produced in all tissues (except the ovaries), converts prostaglandin H2 to prostaglandin D2. Cystatin C, a competitive inhibitor of cysteine proteases, is produced by all nucleated cells. Both have been purported to be novel markers of glomerular filtration [93] . In acutely decompensated heart failure patients, both BTP and cystatin C predicted risk of death and/or heart failure hospitalizations and were superior to creatinine, estimated glomerular filtration rate, and blood urea nitrogen [93] . However, characterization of these biomarkers specifically in DCM has not been evaluated and merits further investigation.
Kidney injury molecule-1 (KIM-1) is a glycoprotein that is expressed in the proximal tubule in renal injury. Both KIM-1 and NGAL levels were increased in patients with LVSD and may provide prognostic information in LVSD patients with mild renal insufficiency. These findings suggest an important role for biomarkers in cardiorenal interactions in heart failure [94] .
Increasing evidence shows that the heart secretes factors to maintain its performance and coordinate cellular activities in response to cardiac stress as outlined previously. However, newer proteins secreted from cardiac tissue have been identified. These cardiac-secreted factors are termed cardiokines. GDF-15 is a stress-responsive cytokine induced by cardiac stress. GDF-15 in conjunction with other biomarkers may add prognostic value for predicting death, overall cardiovascular events, and heart failure in community-based studies [95] . Importantly, elevated circulating levels of GDF-15 are evident in end-stage DCM patients at the time of LVAD implantation, where levels decrease after mechanical unloading. GDF-15 correlates with myocardial fibrosis and kidney function [96] .
Follistatin-like 1 (Fstl1), also referred to as TSC36 (TGF-β stimulating clone 36), is a divergent member of the follistatin family of extracellular glycoproteins, which functions in a noncanonical manner relative to other family members. Fstl1 is poorly understood with regard to its function, but has been shown to suppress cell growth and invasion. Fstl1 has both anti-inflammatory [97, 98] and pro-inflammatory [99] actions. Fstl1 is also regulated in human heart failure. In a collaborative effort between the Sam and Eschenhagen laboratories, we examined the protein expression of Fstl1 in failing explanted human myocardium. Circulating Fstl1 levels were measured in a well-characterized cohort of chronic heart failure patients with LVSD. Fstl1 levels were significantly elevated and associated with LV hypertrophy and circulating levels of BNP [100] . Other groups have shown that myocardial Fstl1 mRNA levels are elevated in severe systolic heart failure that return to normal when LV function recovers after LVAD explantation [101] .
In this review, newer and perhaps mechanistically more important biomarkers in DCM (and likely other cardiomyopathies) were selected, as they confer predictive and prognostic abilities in symptomatic and asymptomatic heart failure patients. Importantly, several of these biomarkers have been evaluated in other cardiomyopathies that have mechanistic overlap (e.g., increased fibrosis in heart failure with preserved ejection fraction (HFpEF), amyloidosis, hypertrophic cardiomyopathy, etc.). Of the aforementioned biomarkers, NTproBNP, BNP, PTX3, GDF-15, galectin-3, and ST2 have been implicated in both the prediction of incident heart failure and the cardiovascular outcomes in HFpEF phenotypes [102] [103] [104] [105] [106] [107] [108] [109] . Osteoprotegerin levels predict cardiovascular outcomes and incident heart failure events in patients with ischemia as well as in chronic ischemic heart failure [110, 111] . Mid-region pro-ADM levels have been shown to predict mortality in light chain cardiac amyloidosis [112] . KIM-1 levels have been implicated not only in LVSD but also in the prediction of incident heart failure [113] . Biomarkers, such as sFAS, MPO, and Fstl1, have been measured in patients with LVSD (and nonischemic etiologies), but not specifically in DCM.
Thus, biomarkers in heart failure provide insight into the pathobiology of the cardiomyopathy and into mechanisms at the myocyte level, the microenvironment, and the macroenvironment. Importantly, they provide diagnostic, predictive, and prognostic information while offering opportunities for potential targets for emerging therapies for heart failure. Measurements of biomarkers, even those that are not independent risk predictors or specific to DCM, remain clinically important as they provide mechanistic information about the pathogenesis of heart failure. Although biomarkers have been studied and validated individually, recent studies have utilized multiple biomarker panels to help augment risk prediction, integrate multiple biologic pathways, and potentially increase specificity in heart failure groups. Ky and colleagues found that a score derived from multiple biomarkers (which encompassed diverse biologic pathways) improved the prediction of adverse events beyond current measures in heart failure patients with LVSD [114] . Similarly recent work from our group in patients with cardiac amyloidosis with LVSD, we showed that biomarkers in aggregate (MMP-2/TIMP-2 in combination with BNP and cTnI) had a potential discriminative ability for distinguishing between the different types of cardiac amyloidosis prompting more invasive diagnostic interventions and presumably therapies in these patients [115] . Furthermore, assessment of these aggregate biomarkers suggests that therapeutic intervention that reduces collagen deposition should be studied in these patients [115] . Thus, a greater focus and emphasis on multiple biomarker panels may be more important and clinically relevant, in terms of detection, prediction, diagnosis specificity, prognosis, and therapeutic response. Combined with clinical assessments, biomarkers may lead to a better understanding of the various types of heart failure, allowing the use of a more personalized approach in identifying and treating patients with LVSD and cardiomyopathy. 
